H. Lundbeck A/S
HLUN-A
Peringkat dalam Saham
#3072
H. Lundbeck A/S engages in the research, development, manufacturing, and... H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Harga Saham
$7.07
Kapitalisasi Pasar
$5.91B
Perubahan (1 hari)
-4.56%
Perubahan (1 tahun)
28.57%
Negara
DK
Perdagangan H. Lundbeck A/S (HLUN-A)
Kategori
Healthcare
Riwayat pemecahan saham untuk H. Lundbeck A/S (HLUN-A)
Saham H. Lundbeck A/S (simbol: HLUN-A) telah mengalami total 0 kali pemecahan saham.
Pemecahan saham terbaru terjadi pada Oct 21, 2026.
Satu lembar saham HLUN-A yang dibeli sebelum Oct 21, 2026 sekarang setara dengan 0 lembar saham HLUN-A.
Pemecahan saham terbaru terjadi pada Oct 21, 2026.
Satu lembar saham HLUN-A yang dibeli sebelum Oct 21, 2026 sekarang setara dengan 0 lembar saham HLUN-A.
Daftar pemecahan saham
| Tahun | Pemecahan | Kelipatan | Kelipatan Kumulatif |
|---|---|---|---|
| Tidak cukup data untuk tanggal yang disediakan. | |||
Pemecahan saham untuk perusahaan sejenis atau pesaing
| Perusahaan | Jumlah pemecahan saham | Kelipatan Kumulatif | Negara |
|---|---|---|---|
| 0 | - |
US
|
|
| 0 | - |
SE
|
|
| 0 | - |
FR
|
|
| 0 | - |
US
|
|
| 0 | - |
IT
|
